New HIV drug IAP086 enters first human safety trial

NCT ID NCT07596888

Recruiting now Disease control Sponsor: University of North Carolina, Chapel Hill Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests whether a single dose of an experimental drug called IAP086 is safe in 30 adults with HIV whose virus is already well-controlled by standard antiretroviral therapy. Participants receive one intravenous infusion and are monitored closely for 28 days. The main goal is to check for side effects, not to measure how well the drug works against HIV.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IAP086 (an experimental drug given as a single intravenous infusion)
What this could lead to: If safe, this could pave the way for larger studies exploring whether IAP086 helps control HIV without daily pills.
What could go wrong: This is a very early, small Phase 1 safety trial in 30 people. It is not designed to test effectiveness, and the drug may cause side effects or fail in later studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1-INFECTION

Contacts and locations

Locations

University of North Carolina
RECRUITING

Chapel Hill, North Carolina, 27514, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.